[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].

福尔菲里 催眠药 贝伐单抗 医学 中止 内科学 结直肠癌 肿瘤科 不利影响 胃肠病学 伊立替康 癌症 化疗
作者
Mina Iwai,Masashi Kimura,Eiseki Usami,Tomoaki Yoshimura
出处
期刊:PubMed 卷期号:49 (6): 687-691
链接
标识
摘要

The addition of anti-angiogenic agents to cytotoxic agents to improve outcomes has become the standard treatment for metastatic colorectal carcinoma. In this study, we evaluated the safety of bevacizumab plus FOLFIRI with that of ramucirumab plus FOLFIRI in second- and later-line treatment in Japanese patients with metastatic colorectal carcinoma. Patients who received ramucirumab or bevacizumab as a second- and later-line treatment between January 2016 and March 2020 were included. Treatment regimens, body surface area, dosage, number of treatment courses, and adverse events( AEs) were evaluated. There were 66 and 17 patients in the bevacizumab plus FOLFIRI and ramucirumab plus FOLFIRI groups, respectively. All patients developed AEs. AEs of grade 3/4 were documented in 84.8% and 100% of the patients in the bevacizumab plus FOLFIRI and ramucirumab plus FOLFIRI groups, respectively. Progressive disease was the most common reason for treatment discontinuation in both groups. Twelve (18.2%) and 5 (29.4%) patients in the bevacizumab plus FOLFIRI and ramucirumab plus FOLFIRI groups, respectively, discontinued treatment due to AEs. The most common AEs leading to discontinuation were malaise and decreased performance status. The findings of our study indicated that both bevacizumab plus FOLFIRI and ramucirumab plus FOLFIRI groups have a high incidence of AEs, and that medical professionals need to be aware of the frequent development of malaise and decreased performance status.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
云宇发布了新的文献求助10
1秒前
lh发布了新的文献求助10
2秒前
li发布了新的文献求助10
2秒前
wenze发布了新的文献求助20
3秒前
寒战发布了新的文献求助10
3秒前
Billy发布了新的文献求助10
3秒前
ghh完成签到,获得积分20
4秒前
5秒前
nung发布了新的文献求助10
5秒前
7秒前
10秒前
10秒前
11秒前
11秒前
12秒前
凛雪鸦发布了新的文献求助10
12秒前
12秒前
小二郎应助lh采纳,获得10
13秒前
15秒前
唐唐完成签到,获得积分10
16秒前
小白菜完成签到 ,获得积分10
17秒前
17秒前
LIM发布了新的文献求助10
17秒前
18秒前
隐形之玉发布了新的文献求助10
18秒前
旭宝儿发布了新的文献求助10
21秒前
21秒前
23秒前
科研通AI2S应助路过的风景采纳,获得10
24秒前
ngyy完成签到 ,获得积分10
24秒前
25秒前
25秒前
畅小狮发布了新的文献求助50
25秒前
liuzengzhang666完成签到,获得积分10
25秒前
汉堡包应助fjsfff采纳,获得10
26秒前
华仔应助Josh采纳,获得10
26秒前
peng发布了新的文献求助10
26秒前
26秒前
Manta完成签到,获得积分10
27秒前
小白菜完成签到 ,获得积分10
28秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3138230
求助须知:如何正确求助?哪些是违规求助? 2789160
关于积分的说明 7790351
捐赠科研通 2445545
什么是DOI,文献DOI怎么找? 1300521
科研通“疑难数据库(出版商)”最低求助积分说明 625925
版权声明 601046